Evofem Biosciences Inc.

1.5600.00Vol 2.90M1Y Perf -70.23%
Apr 16th, 2021 16:00 DELAYED
BID1.56 ASK1.58
Open1.57 Previous Close1.56
Pre-Market- After-Market-
 - -  - -%
Target Price
5.50 
Analyst Rating
Strong Buy 1.00
Potential %
252.56 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/45 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/-34 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/-23 
Income Ranking
 —    -
Market Cap129.67M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
1.12 
Earnings Date
5th May 2021

Today's Price Range

1.501.58

52W Range

1.506.87

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-10.86%
1 Month
-45.83%
3 Months
-42.65%
6 Months
-45.45%
1 Year
-70.23%
3 Years
-76.44%
5 Years
-65.79%
10 Years
-

TickerPriceChg.Chg.%
EVFM1.560.00000.00
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
0.60
1.30
0.96
63.80
-
Leverage Ratio 3.40
ProfitabilityValueIndustryS&P 500US Markets
-4.90
-29 009.00
-28 920.50
-
-
RevenueValueIndustryS&P 500US Markets
446.00K
0.01
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.36-0.50-38.89
Q03 2020-0.44-0.3325.00
Q02 2020-0.37-0.39-5.41
Q01 2020-0.33-0.40-21.21
Q04 2019-0.29-0.276.90
Q03 2019-0.31-0.303.23
Q02 2019-0.35-0.350.00
Q01 2019-0.45-0.50-11.11
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.49-16.67Negative
6/2021 QR-0.38-8.57Negative
12/2021 FY-1.54-25.20Negative
12/2022 FY-0.96-45.45Negative
Next Report Date5th May 2021
Estimated EPS Next Report-0.49
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume2.90M
Shares Outstanding83.12M
Trades Count7.39K
Dollar Volume9.19M
Avg. Volume4.53M
Avg. Weekly Volume2.90M
Avg. Monthly Volume4.75M
Avg. Quarterly Volume4.86M

Evofem Biosciences Inc. (NASDAQ: EVFM) stock closed at 1.56 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 2.94M shares and market capitalization of 129.67M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Evofem Biosciences Inc. CEO is Saundra Pelletier.

The one-year performance of Evofem Biosciences Inc. stock is -70.23%, while year-to-date (YTD) performance is -35.27%. EVFM stock has a five-year performance of -65.79%. Its 52-week range is between 1.5 and 6.87, which gives EVFM stock a 52-week price range ratio of 1.12%

Evofem Biosciences Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 153.09, a price-to-sale (PS) ratio of 307.99, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -202.18%, a ROC of -180.09% and a ROE of -1 549.32%. The company’s profit margin is -%, its EBITDA margin is -28 920.50%, and its revenue ttm is $446.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Evofem Biosciences Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.49 for the next earnings report. Evofem Biosciences Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Evofem Biosciences Inc. is Strong Buy (1), with a target price of $5.5, which is +252.56% compared to the current price. The earnings rating for Evofem Biosciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evofem Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evofem Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.11, ATR14 : 0.32, CCI20 : -90.65, Chaikin Money Flow : -0.26, MACD : -0.52, Money Flow Index : 21.02, ROC : -9.83, RSI : 28.33, STOCH (14,3) : 11.43, STOCH RSI : 0.00, UO : 39.18, Williams %R : -88.57), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evofem Biosciences Inc. in the last 12-months were: Justin J. File (Buy at a value of $26 690), Kelly Culwell (Sold 2 000 shares of value $9 410 ), Kim P. Kamdar (Buy at a value of $14 700), Lisa Dale Rarick (Buy at a value of $31 395), Russell Barrans (Buy at a value of $8 950), Saundra Pelletier (Buy at a value of $103 168), Saundra Pelletier (Sold 122 500 shares of value $399 350 ), William Hall (Buy at a value of $14 250)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
3 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Evofem Biosciences Inc.

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Its focus is to advance the quality of life for women by developing solutions such as hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections. Its first commercial product, Phexxi (lactic acid, citric acid, and potassium bitartrate) vaginal gel, is for the prevention of pregnancy. Phexxi is hormone-free, female-controlled, on-demand prescription contraceptive gel. Its pipeline product candidate, EVO100, is being evaluated for the prevention of chlamydia and gonorrhea - two of the pervasive sexually transmitted diseases in the United States.

CEO: Saundra Pelletier

Telephone: +1 858 550-1900

Address: 12400 High Bluff Drive, San Diego 92130, CA, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

53%47%

Bearish Bullish

50%50%

Bearish Bullish

54%46%

News

Stocktwits